(This is associative evidence and may reflect confounding by indication, surveillance patterns, and glycaemic differences.) For post-marketing pharmacovigilance, FAERS-based analyses of semaglutide identify multiple safety signals (e.g., gastrointestinal obstruction-related terms, dehydration/volume depletion in some GLP-1RA analyses), but vulvovaginal dryness/infection/discharge/pain are not prominent as labelled risks in the major semaglutide FAERS disproportionality paper retrieved here
Bangha, E., Elsner, P., & Kistler, G
Retatrutide is a novel triagonist peptide that simultaneously targets three critical metabolic receptors: Glucagon-like peptide-1 (GLP-1) Glucose-dependent insulinotropic polypeptide (GIP) Glucagon Originally developed for clinical research into obesity and metabolic disorders, retatrutide is designed to support extensive scientific exploration of: Weight reduction Improved glucose management Enhanced metabolic function What Key Benefits Does Retatrutide Offer
In contrast to traditional one-size-fits-all drug development, Pain Cloud harnesses advanced in-silico techniques and big data to guide the discovery of targeted pain treatments identifying the optimal patient groups from over 1000 conditions for research targets
So, a couple of times a week, I get up and go for a walk outside, first thing